Establishment 5 doses presentation of the triple viral vaccine without albumin to reduce loss during administration

Abstract

the established approval limits. Conclusion: The results demonstrate that only the 5-dose presentation, with a 67% reduction in filling volume, replacement of the current vial model and recalculation of vaccine component concentrations, maintains the productive capacity with the number of doses per batch produced, in the same time and lyophilization cycle currently used.